Quanterix (NASDAQ: QTRX) reported Q4 EPS of ($0.30), $0.07 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $35.16 million versus the consensus estimate of $35.25 million.

GUIDANCE:

Quanterix sees FY2025 revenue of $140-146 million, versus the consensus of $154.7 million.
This estimate excludes revenue from Lucent Diagnostics testing. The Company expects gross margin to be in the range of 59 to 63%, and adjusted gross margin (non-GAAP) in the range of 53% to 57%. Finally, the Company anticipates 2025 cash usage (change in cash, cash equivalents, marketable securities, and restricted cash) to be approximately $55.0 million to $65.0 million, which includes $20.0 million of upfront payments for the EMISSION acquisition. The estimated cash usage excludes any expenses or payments related to the pending Akoya acquisition.

For earnings history and earnings-related data on Quanterix (QTRX) click here.